Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.

Literature DB >> 20798199

Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.

Sin Jen Ong¹, Marissa Teo, Kiat Hon Lim, Su Pin Choo, Han Chong Toh.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20798199 PMCID： PMC3228032 DOI： 10.1634/theoncologist.2010-0118

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

× No keyword cloud information.

13 in total

1. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.

Authors: T Kotoh; D K Dhar; R Masunaga; H Tabara; M Tachibana; H Kubota; H Kohno; N Nagasue
Journal: Surgery Date: 1999-05 Impact factor: 3.982

2. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

Authors: Toshihiko Doi; Kei Muro; Narikazu Boku; Yasuhide Yamada; Tomohiro Nishina; Hiroya Takiuchi; Yoshito Komatsu; Yasuo Hamamoto; Nobutsugu Ohno; Yoshie Fujita; Matthew Robson; Atsushi Ohtsu
Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544

3. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.

Authors: Sven A Lang; Andreas Gaumann; Gudrun E Koehl; Ulrike Seidel; Frauke Bataille; Dagmar Klein; Lee M Ellis; Ulrich Bolder; Ferdinand Hofstaedter; Hans-Jürgen Schlitt; Edward K Geissler; Oliver Stoeltzing
Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396

4. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.

Authors: Z H Khan; E J Simpson; A T Cole; M Holt; I MacDonald; D Pye; A Austin; J G Freeman
Journal: Aliment Pharmacol Ther Date: 2003-03-01 Impact factor: 8.171

5. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Authors: Noopur Raje; Shaji Kumar; Teru Hideshima; Kenji Ishitsuka; Dharminder Chauhan; Constantine Mitsiades; Klaus Podar; Steven Le Gouill; Paul Richardson; Nikhil C Munshi; David I Stirling; Joseph H Antin; Kenneth C Anderson
Journal: Blood Date: 2004-08-19 Impact factor: 22.113

6. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?

Authors: J Boone; F J W Ten Kate; G J A Offerhaus; P J van Diest; I H M Borel Rinkes; R van Hillegersberg
Journal: J Clin Pathol Date: 2008-05-12 Impact factor: 3.411

7. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.

Authors: Guanzhen Yu; Jiejun Wang; Ying Chen; Xi Wang; Jun Pan; Gang Li; Zhiliang Jia; Qiang Li; James C Yao; Keping Xie
Journal: Clin Cancer Res Date: 2009-02-17 Impact factor: 12.531

8. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.

Authors: Chia-Jui Yen; Julie G Izzo; Dung-Fang Lee; Sushovan Guha; Yongkun Wei; Tsung-Teh Wu; Chun-Te Chen; Hsu-Ping Kuo; Jung-Mao Hsu; Hui-Lung Sun; Chao-Kai Chou; Navtej S Buttar; Kenneth K Wang; Peng Huang; Jaffer Ajani; Mien-Chie Hung
Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701